Latest news
Prostate Cancer Value Starts Counting Cognition
ARACOG data presented at ASCO showed less cognitive decline with darolutamide than enzalutamide, bringing memory, attention and daily function into the prostate cancer treatment-value debate.
Huntington Gene Therapy Hits the Evidence Wall
Rare Disease Policy Moves Into the Individualised Therapy Era
Digital Mental Health Still Has an Evidence Problem
Alzheimer’s Access Now Starts With Genotyping and MRI Capacity
Europe’s Mental Health Projects Move From Crisis Talk to Delivery Tools
Europe’s Epilepsy Rules Start Catching Up With Precision Treatment
SMA Screening Shows Precision Neurology Starts Before Symptoms
Post-Stroke Cognitive Screening Needs Local Tools
Europe’s Stroke Plan Turns Speed Into a Policy Test
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.